Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial
Author:
Publisher
Elsevier BV
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference23 articles.
1. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries;Domper Arnal;World J Gastroenterol,2015
2. Trends in survival for both histologic types of esophageal cancer in U.S. surveillance, epidemiology and end results areas;Polednak;Int J Cancer,2003
3. Palliative chemotherapy does not improve survival in metastatic esophageal cancer;Adenis;Oncology,2010
4. Esophageal carcinoma;Pennathur;Lancet,2013
5. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction;Homs;Cochrane Database Syst Rev,2006
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Cost-effectiveness analysis of Tislelizumab vs. Camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma;2023-05-03
2. Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China;Frontiers in Pharmacology;2023-03-02
3. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China;Therapeutic Advances in Medical Oncology;2023-01
4. Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma;Frontiers in Oncology;2022-12-06
5. Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China;Frontiers in Public Health;2022-06-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3